Mirum Pharmaceuticals (NASDAQ:MIRM) Research Coverage Started at Raymond James

Share on StockTwits

Raymond James began coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a research report released on Monday morning, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $28.00 price objective on the stock.

A number of other equities analysts also recently issued reports on the company. Guggenheim started coverage on Mirum Pharmaceuticals in a report on Monday. They issued a buy rating and a $18.00 price target for the company. Evercore ISI started coverage on Mirum Pharmaceuticals in a report on Monday. They issued an outperform rating and a $25.00 price target for the company. Finally, Citigroup started coverage on Mirum Pharmaceuticals in a report on Monday. They issued a buy rating and a $21.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, The company presently has an average rating of Buy and a consensus price target of $25.00.

Shares of Mirum Pharmaceuticals stock opened at $13.45 on Monday. Mirum Pharmaceuticals has a one year low of $12.05 and a one year high of $15.50.

In other news, Director Patrick J. Heron acquired 450,000 shares of Mirum Pharmaceuticals stock in a transaction on Monday, July 22nd. The stock was bought at an average price of $15.00 per share, for a total transaction of $6,750,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James E. Flynn acquired 332,000 shares of Mirum Pharmaceuticals stock in a transaction on Monday, July 22nd. The stock was purchased at an average price of $15.00 per share, with a total value of $4,980,000.00. The disclosure for this purchase can be found here. Insiders purchased 1,357,000 shares of company stock valued at $20,355,000 over the last ninety days.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

Recommended Story: What is a Buy-Side Analyst?

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mirum Pharmaceuticals  Research Coverage Started at Raymond James
Mirum Pharmaceuticals Research Coverage Started at Raymond James
i3 Verticals  PT Raised to $28.00
i3 Verticals PT Raised to $28.00
PTC Therapeutics’  Hold Rating Reaffirmed at Barclays
PTC Therapeutics’ Hold Rating Reaffirmed at Barclays
Halozyme Therapeutics  Receives “Sell” Rating from Barclays
Halozyme Therapeutics Receives “Sell” Rating from Barclays
Eiger Biopharmaceuticals  Earns “Buy” Rating from LADENBURG THALM/SH SH
Eiger Biopharmaceuticals Earns “Buy” Rating from LADENBURG THALM/SH SH
Intec Pharma  Earns Hold Rating from LADENBURG THALM/SH SH
Intec Pharma Earns Hold Rating from LADENBURG THALM/SH SH


© 2006-2019 Ticker Report